Feature Papers of Hepatitis A, B, C and E Vaccines

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Hepatitis Virus Vaccines".

Deadline for manuscript submissions: 31 March 2024 | Viewed by 202

Special Issue Editor

1. Division of Veterinary Medicine, Paul Ehrlich Institute, Langen, Germany
2. European Virus Bioinformatics Center (EVBC), Jena, Germany
Interests: coronavirus; SARS-CoV-2; variant of concern; vaccine evaluation; T Lymphocytes; HBV
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Hepatitis A, B, C, D and E are viral infections causing liver damage and, in severe cases, leading to liver failure. Hepatitis A and E are typically transmitted through contaminated water and food, whereas hepatitis B and C are mainly spread through blood-to-blood contact or sexual transmission. Hepatitis D virus is a satellite because it can only propagate in the presence of the hepatitis B virus.

Nowadays, vaccines are available for hepatitis A and B, and they are highly effective in preventing infection. The hepatitis A vaccine is advised for individuals traveling to areas with high prevalence of hepatitis A or who work in high-risk professions. The hepatitis B vaccine is recommended for all infants, children, and adults who are at high risk of infection. There is no vaccine for hepatitis D, since prevention of hepatitis B with hepatitis B vaccine also protects against hepatitis D infection. For hepatitis C, there is no vaccine available, but new treatment options involving a combination of direct-acting antivirals have been developed that can cure the infection in most patients. Hepatitis E vaccine is available in China but not globally. The widespread use of vaccines is a crucial means of preventing hepatitis infections, and it can lead to a substantial reduction in the overall burden of these diseases.

As a Section Editorial Board Member of Hepatitis Virus Vaccines, I am pleased to announce the Special Issue titled "Feature Papers of Hepatitis A, B, C and E Vaccines". This Special Issue invites manuscripts related to the development of vaccines and immunotherapy treatments for hepatitis A, B, C, and E. We also encourage studies on vaccination attitudes, pathogenesis, animal models, clinical manifestations and disease associations. Manuscript submissions are welcome from both Editorial Board Members and outstanding scholars. Please send short proposals for submissions of Feature Papers to our Editorial Office for evaluation.

Dr. Bingqian Qu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

This special issue is now open for submission.
Back to TopTop